TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

13 Feb 2025 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS

11 Feb 2025 06:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2025 Outlook

13 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

25 Nov 2024 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Nov 2024 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

12 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

07 Nov 2024 20:05:37 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Proposed Public Offering of Common Stock

07 Nov 2024 15:01:18 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

04 Nov 2024 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2024 Financial Results

31 Oct 2024 06:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

26 Oct 2024 06:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2024 Financial Results

21 Oct 2024 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

17 Oct 2024 06:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

14 Oct 2024 15:30:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

26 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Sep 2024 16:00:00 By Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

10 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

05 Sep 2024 16:34:13 By Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

22 Aug 2024 15:30:00 By Nasdaq GlobeNewswire